Impact of drug therapy on benign prostatic hyperplasia-specific quality of life

By Rhodes P.R.   Krogh R.H.   Bruskewitz R.C.  

Urology, Vol. 53, Iss. 6, 1999-06 ,pp. : 1090-1098

Elsevier

Access to resources Recommend Favorite

Prostate-Specific Antigen as an Estimator of Prostate Volume in the Management of Patients with Symptomatic Benign Prostatic Hyperplasia

By Mochtar C.A.   Kiemeney L.A.L.M.   van Riemsdijk M.M.   Barnett G.S.   Laguna M.P.   Debruyne F.M.J.   de la Rosette J.J.M.C.H.  

European Urology, Vol. 44, Iss. 6, 2003-12 ,pp. : 695-700

Elsevier

Access to resources Recommend Favorite

Latin American study on patient acceptance of the international prostate symptom score (IPSS) in the evaluation of symptomatic benign prostatic hyperplasia

By Netto N.R.   de Lima M.L.   de Andrade E.F.M.   Apuzzo F.   da Silva M.B.   Davidzon I.M.   Moises M.J.   Chamma E.J.   Bogado H.  

Urology, Vol. 49, Iss. 1, 1997-01 ,pp. : 46-49

Elsevier

Access to resources Recommend Favorite

Impact of prostate size on the outcome of transurethral laser evaporation of the prostate for benign prostatic hyperplasia

By Narayan P.   Tewari A.   Fournier G.   Toke A.  

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 776-782

Elsevier

Access to resources Recommend Favorite

Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

By Eckhardt M.D.   van Venrooij G.E.P.M.   Boon T.A.  

Urology, Vol. 57, Iss. 4, 2001-04 ,pp. : 695-700

Elsevier

Access to resources Recommend Favorite